The FDA issued a draft guidance for industry titled, “Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products” This guidance makes recommendations to sponsors and investigators considering the use of externally controlled clinical trials to show evidence of the safety and effectiveness of a drug.
The guidance provides stakeholders with considerations for designing and conducting externally controlled trials that use patient-level data (i.e., information on individual people, such as medical and treatment history) to study the effectiveness and safety of drugs, including threats to the validity of trial results from sources of potential bias. The external data can include data from other clinical trials or from real-world data sources such as registries, electronic health records, or medical claims. This guidance also describes considerations for communicating with FDA and ensuring the agency has access to data from an externally controlled trial.
The recommendations in this guidance can advance opportunities and efficiencies for sponsors and improve the design and conduct of externally controlled trials.
This draft guidance is part of a series of guidances FDA has already published, or plans to publish, as part of the agency’s RWE Program and in support of the 21st Century Cures Act and the Prescription Drug User Fee Act.
For more information on the draft guidance and how to comment, please see the Federal Register Notice.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!